JH-RE-06

CAT: 0804-HY-126214-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-126214-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy[1][2].
CAS Number
[1361227-90-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jh-re-06.html
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C(C(CC(C)C)=O)=C(NC2=C(Cl)C=C(Cl)C=C2)NC3=C1C([N+]([O-])=O)=CC=C3Cl
Molecular Formula
C20H16Cl3N3O4
Molecular Weight
468.72
Precautions
H302, H315, H319
References & Citations
[1]Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178 (1) :152-159.e11.|[2]REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9 (8) :OF17.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-125001JH-VIII-49
HY-130837-01JH-LPH-28
HY-130838-01JH-LPH-33
HY-16936-01JH-II-127
HY-144614JH-XVII-10
HY-149489JH-131e-153
HY-139875-01JH-XVI-178
HY-170616JH-FK-08
HY-125008JH-IX-179
HY-168649-01JH-LPH-107

Alternative Products

CatalogName
M22367-01JH-RE-06
A19168-1JH-RE-06 1mg
A19168-100JH-RE-06 100mg
A19168-25JH-RE-06 25mg
A19168-5JH-RE-06 5mg
A19168-10JH-RE-06 10mg
A19168-50JH-RE-06 50mg
A19168-10mM-DJH-RE-06 10mM * 1mL in DMSO
MBS3607037JH-T4
4322/2JH 295

Popular Products